Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

View the BIG 100 largest medical device companies in the world listings here

BioMérieux logo

BioMérieux

Rank: 29
2020 Rank: 34

Headquarters: Marcy-l'Étoile, France

2021 Revenues ($USD) : $3,554,748,000
2021 Revenues (foreign currencies) : € 3,118,200,000
2021 R&D spend : $454,632,000
2021 Number of Employees : 13,000
Fiscal Year End : 12/31/2020
Key People : Alexandre Mérieux, chairperson and CEO; Pierre Boulud, chief operating officer, clinical operations; Guillaume Bouhours, EVP, CFO, purchasing, information systems; Pierre Charbonnier, EVP, global quality, manufacturing and supply chain; François Lacoste, EVP, R&D; Valérie Leyldé, EVP, human resources and communications; Mark Miller, EVP, chief medical officer; Yasha Mitrotti, EVP, industrial microbiology; Esther Wick, EVP, legal, IP and compliance.

About the company: An important player in the in vitro diagnostics space for more than 55 years, BioMérieux has a presence in 44 countries and serves more than 160 countries with the support of large distributors. The company provides a wide range of diagnostic systems, reagents, software and services to detect diseases and contamination, improve people’s health, and bolster consumer safety. An upturn in U.S. respiratory panels demand amid the COVID-19 Delta variant wave pushed sales up 12% through the first nine months of 2021. In October, BioMérieux and Baxter announced CE mark approval for their Nephroclear CCL14 test to predict persistent severe acute kidney injury. –CN
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech